<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548778</url>
  </required_header>
  <id_info>
    <org_study_id>fPELA_ClinPerform2020</org_study_id>
    <nct_id>NCT04548778</nct_id>
  </id_info>
  <brief_title>BÜHLMANN fPELA in the Diagnosis of Exocrine Pancreatic Insufficiency</brief_title>
  <official_title>Clinical Evaluation of BÜHLMANN Fecal Pancreatic Elastase (fPELA) Tests in the Diagnosis of Exocrine Pancreatic Insufficiency (PEI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bühlmann Laboratories AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bühlmann Laboratories AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study shall determine the clinical performance of the BÜHLMANN fecal pancreatic elastase&#xD;
      (fPELA) assays in the diagnosis of exocrine pancreatic insufficiency (PEI).&#xD;
&#xD;
      This is a observational and cross-sectional performance study. Specimens and clinical data&#xD;
      are collected by a single study site.&#xD;
&#xD;
      Included are subjects for which pancreatic elastase testing was indicated due to a suspected&#xD;
      exocrine pancreatic insufficiency and which were at least 18 years of age. Subjects which&#xD;
      suffered from diarrhea (stool water content ≥ 75%) at the time of sample collection are&#xD;
      excluded from the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Performance of BÜHLMANN fPELA assays in the diagnosis of PEI</measure>
    <time_frame>December 2021</time_frame>
    <description>Diagnostic sensitivity and specificity of BÜHLMANN fPELA assays</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Exocrine Pancreatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>exocrine pancreatic insufficiency (PEI)</arm_group_label>
    <description>Established diagnosis of PEI based on a routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no exocrine pancreatic insufficiency (no PEI)</arm_group_label>
    <description>No evidence of PEI according to routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BÜHLMANN fPELA assay</intervention_name>
    <description>BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.</description>
    <arm_group_label>exocrine pancreatic insufficiency (PEI)</arm_group_label>
    <arm_group_label>no exocrine pancreatic insufficiency (no PEI)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Included are subjects for which pancreatic elastase testing was indicated due to a&#xD;
        suspected exocrine pancreatic insufficiency and which were at least 18 years of age.&#xD;
        Following patient groups show an increased risk for developing an exocrine insufficiency:&#xD;
        chronic pancreatitis, cystic fibrosis, diabetes, pancreatic resection. Eligible study&#xD;
        subjects provide one stool sample which is forwarded to the study site within three days.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  suspected exocrine pancreatic insufficiency&#xD;
&#xD;
          -  at least 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diarrhea (stool water content ≥ 75%) at the time of sample collection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Rosendahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum der Martin-Luther-Universität Halle-Wittenberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Neu, PhD</last_name>
    <phone>+ 41 61 487 12 12</phone>
    <email>sn@buhlmannlabs.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicja Ritz, PhD</last_name>
    <phone>+ 41 61 487 12 12</phone>
    <email>alr@buhlmannlabs.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonas Rosendahl, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

